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MICRO-ABSTRACT 
In our study, we evaluated the quality of life of young women experiencing chemotherapy-
induced menopause. Our results underline that age and pre-treatment AMH level could be 
helpful to predict the menopause but these results have to be confirmed in further studies. At 6 
months post-chemotherapy, the EORTC QLQ-BR23 questionnaire tended to highlight an 
impaired quality of life in menopaused patients.  
 
ABSTRACT 
Background: Young breast cancer patients treated with chemotherapy can experience ovarian 
failure, which can lead to chemotherapy-induced menopause (CIM) impacting the quality of 
life (QoL). A prospective study was set out to evaluate the impact of CIM on QoL in women 
of childbearing age with non-metastatic breast cancer and this article reports results of the 
interim analysis conducted to evaluate feasibility and to see preliminary results. 
Patients and Methods: 58 women (18-46 years) with newly-diagnosed breast cancer and 
treated with chemotherapy were eligible. QoL was assessed by self-administered 
questionnaires (QLQ-C30, QLQ-BR23 and Kupperman index) and hormonal variations 
(AMH, FSH and estradiol) were explored. We compared patients with ≥12 months 
amenorrhea (CIM, n=41) to patients with <12 months of amenorrhea (non-CIM, n=17).  
Results: A good inclusion rate (4/month approx.) and sufficient data enabled us to perform 
this analysis. QLQ-C30 failed to show any difference between CIM and non-CIM patients 
(p=0.5). In contrast, at 6 months post-chemotherapy, CIM patients tended to have lower QoL 
as shown by QLQ-BR23 (p=0.16) and more severe climacteric symptoms (p=0.01). 
Regarding hormonal variations, AMH pre-treatment level was higher in non-CIM patients 
(p=0.0032). We also noted that CIM patients were older (p=0.00013), had shorter 
menstruation cycle (p=0.082), and experienced faster amenorrhea (p=0.088). 
Conclusions: The study is technically feasible and our preliminary results underline that age 
in association with pre-treatment AMH level could be helpful to predict ovarian function. 
QLQ-BR23 seemed to be stronger, more precise and appropriate to evaluate QoL changes in 
breast cancer patients than the QLQ-C30.  
Key words: Breast cancer, young women, chemotherapy-induced menopause, quality of life, 
hormonal variations 
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TEXT 
Introduction 
Breast cancer is the most common cancer among women, and about 12-20% of patients are in 
childbearing agepremenopausal.
1–3
 Young women with breast cancer are known to have the 
poorest prognosis due to the aggressiveness of the tumour, and they are mostly treated with 
chemotherapy.
4,5
 Despite the fact that chemotherapy improves survival and reduces the risk of 
recurrence
6,7
, it could cause ovarian failure leading to chemotherapy-induced amenorrhea 
(CIA) or premature menopause.
1,8
 Some studies reported the complexities in defining the 
natural menopause but it is even more difficult in the case of young women treated by 
chemotherapy.
9,10
 
According to the World Health Organization (WHO), menopause is characterized by at least 
one year of amenorrhea.
11
 Other definitions found in the literature vary considerably and 
describe menopause as a minimum of 1 to 2 years of amenorrhea.
12,13
 Hormonal changes are 
also considered for its definition. Among post-menopausal women, anti-mullerian hormone 
(AMH) and estradiol serum levels decrease while follicle-stimulating hormone (FSH) serum 
level increases.
14
 Currently, AMH is considered to be a good marker of ovarian reserve
15
 and 
could play a role in the prediction of chemotherapy-induced menopause (CIM) in young 
cancer patients.
16
 
Today, patient quality of life (QoL) is a central concern and an integral part of medical 
care.
17–19
 Some studies have documented impaired QoL in breast cancer survivors.   In 
particular, young breast cancer patients are at greater risk of  impaired health-related quality 
of life, including psychological disturbance, sexual problems or physical changes but very 
few studies have examined the specific case of women experiencing CIM.
18,20–23
Moreover, 
the clear identification of menopause in patients treated by chemotherapy could be helpful to 
determine the appropriate endocrine therapy (eg. Tamoxifen or Aromatase Inhibitors) when 
hormone receptors are expressed.
18,20,23
 
 
In order to clarify these issues, we conducted a prospective study (MENOCOR) on young 
women diagnosed with non-metastatic breast cancer. The primary endpoint is to assess the 
impact of CIM on the functional dimension of QoL using the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-
C30) functional score. The secondary endpoints are hormonal variations (AMH, estradiol and 
FSH) and specific aspects of QoL based on menopausal status. An interim analysis of this 
study was performed to determine the feasibility of the study and see the preliminary results. 
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METHODS 
Patients 
Eligible patients were women aged 18-45 years, with stage I-III breast cancer, without 
amenorrhea and scheduled for treatment with adjuvant or neoadjuvant chemotherapy. Age 
over 45 years, metastatic cancer, previous chemotherapy or hormonotherapy, hysterectomy or 
oophorectomy, and menopause were exclusion criteria. A total of 240 patients are expected to 
participate in this study and an interim analysis was scheduled after the inclusion of at least 60 
patients with outcomes at 1.5 years follow-up, i.e. 12 months post-chemotherapy. 
 
Study design 
This is a prospective, multicenter study, approved by the CPP Sud Est VI Ethics Committee 
(08/11/2013) and registered at ClinicalTrials.gov (NCT02102568). A total of 63 patients were 
enrolled from April 2014 to June 2015 in the 3 participating centers: Jean Perrin Cancer 
Center (Clermont-Ferrand), Lucien Neuwirth Cancer Institute (Saint-Etienne) and Jean 
Godinot Cancer Institute (Reims). All patients provided informed consent.  
After enrolment, patients were asked about their medical and gynaecological history. Breast 
cancer characteristics and physical activity were also recorded. Before chemotherapy, a 
complete biology report was drawn up for each patient according to the study provisions in 
order to ascertain the eligibility of the patient. The duration of patient participation in the trial 
is about 3 years with an average of 6 months chemotherapy and a follow-up of 2.5 years (Fig. 
1).  
 
Study endpoints 
This interim analysis has been planned in order to evaluate the feasibility of the study: rhythm 
of inclusion, patients’ responses and data collection. Preliminary results concerning the 
incidence of women with 12 months of amenorrhea, the primary endpoint, the Quality of Life 
Questionnaire – Breast 23 (QLQ-BR23) scores, vasomotor symptoms and their hormonal 
variations were evaluated for this interim analysis. It was conducted after the enrolment of 63 
patients in the study, 1.5 years after inclusion, i.e. 12 months after chemotherapy. These 
results will be compared to data available at the end of the study and we will see if the 12 
months of amenorrhea is predictive of menopause or not.  
Because this study does not expose patients to a supplementary risk, this interim analysis will 
not request an interruption of inclusions.  
 
Menopausal status 
To identify the menopausal status of each patient at the end of the study and classify them into 
2 groups – chemotherapy-induced menopause (CIM) and absence of chemotherapy-induced 
menopause (non-CIM) - information about their menstruation cycle was collected throughout 
the study and menopause was defined as ≥ 2 years of amenorrhea. For this purpose, each 
patient was asked about the dates of her last menstruation before enrolment, before every 
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chemotherapy cycle and at each follow-up, the time to onset of amenorrhea if present, the 
return of menstruation if applicable and the duration of amenorrhea. A calendar where 
patients noted their menstruation dates was issued at inclusion.  
In order to perform the interim analysis conducted on data available at 1.5 years follow-up, 2 
groups of patients were defined according to their amenorrhea duration and menopause is 
characterised by at least one year of amenorrhea as defined by the WHO
11: CIM with ≥ 12 
months of amenorrhea and non-CIM with < 12 months of amenorrhea.  
 
Self-administered questionnaires 
To assess quality of life, patients were asked to complete the questionnaires several times 
during their participation in the study: at inclusion before chemotherapy (V0), at the end of 
chemotherapy (V1), 6 months (V2), 18 months (V3) and 30 months (V4) post-chemotherapy 
(Fig.1). In accordance with the study, this interim analysis focused on data available at 
inclusion, at the end of the treatment (approximately 6 months follow-up) and at 6 months 
post-chemotherapy (i.e. 1 year follow-up). 
The primary outcome, i.e. the impact of CIM on functional QoL, was assessed using the 
QLQ-C30 functional score.
24
 The EORTC QLQ-C30 evaluates general QoL in oncology, it is 
divided into 3 scores: symptom, functional and global, and comprises a total of 30 items. The 
functional part of this questionnaire comprises 15 items divided into 5 dimensions: physical 
activity, daily activity, emotional status, cognition and social life. The total functional score is 
a percentage calculated by the average of all dimensions. In the STIC RMI study,
25
 
menopaused women scored 5 points lower for the QLQ-C30 functional score compared to 
non-menopaused women, so the same difference was expected between our CIM and non-
CIM patients after 2 years of amenorrhea. For this interim analysis, conducted only 6 months 
after chemotherapy, the differential of variation between the CIM and non-CIM groups is 
evaluated. A high score indicates good QoL.
24
 
The EORTC QLQ-BR23 is used in combination with the EORTC QLQ-C30 and addresses 
specific issues of breast cancer. Like the QLQ-C30, it contains two dimensions, one for 
symptoms and the other one for functions with a total of 23 items scored from 1 to 4. It 
particularly investigates body image, sexuality and pain. The total score is a percentage 
calculated by the average of all dimensions. In our study, a high score indicates good QoL.
26
 
The Kupperman index is a specific questionnaire on climacteric symptoms. It contains 11 
items with scores ranging from 0 to 3. The global score is calculated by attributing a specific 
weight to each item, and can vary from 0 to 51. A higher score indicates more severe 
climacteric symptoms.
27
 
Because of the large number of questionnaires used in this study, this interim analysis focused 
on the most relevant results.  
 
Hormones  
In order to study hormone variations (AMH, estradiol and FSH) for menopause prediction, 
measurements were conducted 2 times: before chemotherapy and one month after 
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chemotherapy. Because no other hormonal dosages are waited for these patients, it allowed us 
to see the preliminary result for this interim analysis. 
Concerning AMH, blood samples were collected and serum levels were measured by an 
external laboratory using electrochemiluminescence immunoassays on Roche Cobas 8000. 
According to the laboratory, AMH is included between 0.7 and 52 pmol/L in women aged 
from 20 to 44 years; between 0.3 and 14.7 pmol/L in women aged from 45 to 50 years and is 
undetectable in menopausal women. The detection threshold was 0.21 pmol/L with a variation 
coefficient < 1.8%.  
Estradiol and FSH were measured in the hospital laboratory or in an ordinary analytical 
laboratory by chemiluminescence immunoassay. Estradiol and FSH in non-menopausal 
women are included between 79 and 1348 pmol/L and 1.7 to 17.5, respectively. In 
menopausal women, estradiol is < 214 pmol/L and FSH is between 12.7 and 132.2 UI/L. The 
detection thresholds were 40 pmol/L and 0.2 UI/L respectively for estradiol and FSH.  
 
Statistical analysis 
Patient characteristics were described using standard distribution parameters: means ± 
standard deviation and [range] for quantitative parameters (and median for non-Gaussian 
distributions), and counts and frequencies (%) for categorical parameters. To study the 
evolution of questionnaire scores over time, a two-way ANOVA model (mixed model) was 
used. Statistical relationships between pairs of variables were explored using Chi²-tests for 
categorical parameters, t-tests or ANOVA when one parameter was quantitative (or the Mann-
Whitney U-test or Kruskal-Wallis H-test in case of non-Gaussian distribution and/or 
heteroscedasticity), and with two quantitative parameters, Pearson’s correlation coefficient (or 
for non-Gaussian distributions, Spearman’s rank correlation). To compare the evolution of 
quantitative parameters before and after chemotherapy, the Student paired t-test was used. A 
multivariate analysis of factors influencing CIM was performed using a logistic regression 
model. All tests were two-sided. Significance was set at the standard p-value of p ≤ 0.05. Data 
management and statistical calculations were performed on SEM software.
28
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RESULTS 
Patient characteristics 
A total of 63 patients were enrolled from April 2014 to June 2015. Among them, 5 were 
excluded from the interim analysis: 1 patient was wrongly included, another died during the 
study, for 2 patients there was too much missing data to perform the analysis and 1 patient 
withdrew her consent (Fig.2). A total of 58 patients were included in this interim analysis and 
their characteristics are shown in Table 1. The median age at enrolment was 40.8 [range 24.7 
– 46]. Ninety-height percent of patients presented a grade II/III tumor and 21% were HER2 
positive.  
 
Feasibility and recruitments 
A total of 63 patients were enrolled in 15 months, which means an average of 4 patients were 
newly included each month. The study expects a total of 240 patients which could be reached 
in approximately 5 years with the same inclusion rate. Of the 58 patients, 78% responded to 
questionnaires (Table 2) and 86% got hormones measurements (Table 3). This amount of data 
was sufficient to enable the calculation of our first estimates.  
 
Menopausal status and chemotherapy-induced amenorrhea 
Among the 58 patients, only one patient did not develop CIA and had regular menstrual 
cycles. Among the other 57 patients, 41 patients (70.7%) had at least 12 months of 
amenorrhea. Two groups of patients were defined on this basis: CIM ≥ 12 months of 
amenorrhea (n= 41) and non-CIM < 12 months of amenorrhea (n= 17) (Fig.2). Each group 
characteristics are shown in Table 1. 
 
Impact of CIM on quality of life 
The number of questionnaires per visit and per group is presented in Table 2. 
QLQ-C30 Functional score  
The QLQ-C30 functional score differed significantly in both patient groups between inclusion 
and 6 months post-chemotherapy (p= 0.013). The score obtained at the end of chemotherapy 
was the lowest for both patient groups (CIM and non-CIM) and differed significantly from 
inclusion (p= 0.0056) and 6 months post-chemotherapy (p= 0.032) (Fig.3a). 
For the entire period (inclusion, end of chemotherapy and 6 months post-chemotherapy), no 
difference was evidenced between CIM and non-CIM patients (p= 0.5). The percentage of 
variation between inclusion and 6 months post-chemotherapy was a 2% decrease versus a 5% 
for CIM and non-CIM patients respectively but this difference was not significant (p= 0.72). 
Concerning the mean score at 6 months post-chemotherapy, the functional score differed only 
by 2 points between CIM and non-CIM patients (77.7 versus 80.0; p= 0.76) (Fig. 3a). 
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The QLQ-BR23 functional score: quality of life among breast cancer patients 
As the QLQ-C30 functional score, the QLQ-BR23 functional score varied significantly in 
both patient groups between inclusion and 6 months post-chemotherapy (p= 0.0025). The 
score obtained at the end of chemotherapy was significantly lower from inclusion for the two 
groups of patients (p= 0.00073). In contrast, difference between the end of chemotherapy and 
6 months post-chemotherapy was not so clear (p= 0.12) (Fig.3b). 
Concerning the comparison of the two groups no difference was evidenced between them for 
the entire period (inclusion, end of chemotherapy and 6 months post-chemotherapy) (p= 
0.33). Between inclusion and 6 months post-chemotherapy CIM patients had a 19% decrease 
while non-CIM had a 3% decrease and this difference was leaning towards significance (p= 
0.16). The comparison at 6 months post-chemotherapy reached near significance (p= 0.17) 
with a lower mean score for CIM patients and a difference of 13 points (44.43 versus 57.26) 
(Fig.3b).  
The Kupperman Index: climateric symptoms 
Between inclusion and 6 months post-chemotherapy, the Kupperman Index showed a clear 
time effect (p <10-7) with an increase of the score at the end of chemotherapy (Fig.3c). 
The comparison between CIM and non-CIM patients was close to being significant (p= 
0.084). As expected, CIM patients had significantly higher Kupperman Index at 6 months 
post-chemotherapy (p= 0.01) (Fig.3c). The specific dimension analysis at 6 months post-
chemotherapy showed nearly significant higher hot flushes and vaginal dryness in CIM 
patients than in non-CIM patients (p= 0.096 and p= 0.091). Mood depression was also 
significantly higher in CIM patients (p= 0.025) (Fig. 3d). 
 
Hormones 
Hormone levels per group and per visit are presented in Table 3.  
AMH variations 
In each group, pre-treatment level of AMH was significantly higher from post-treatment level 
(p < 10
-7
) (Fig.4a).  
By comparing the two groups of patients, it revealed that the variation of AMH level between 
inclusion and the end of chemotherapy was different, with a greater decrease in non-CIM 
patients (p= 0.0054). Of course, the pre-treatment level was significantly higher in non-CIM 
patients (p= 0.0032) but no difference was evidence for the post-treatment level (p= 0.26) 
(Fig.4a) (Table 3).  
The analysis also showed a negative correlation between age and initial AMH - the older the 
patients were, the greater the decrease in AMH levels was (r²= 0.38; p= 1.10
-6
) (Fig. 4b). 
FSH variations 
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Between enrolment and after chemotherapy, the FSH level increased significantly in both 
groups of patients (p < 10
-7
) (data not shown).  
No difference was observed between CIM and non-CIM patients for the variation of FSH 
level between these 2 periods (p= 0.25). The difference between CIM and non-CIM patients 
was nearly significant for the pre-treatment level of FSH (10 UI/L versus 5 UI/L; p= 0.07) 
with a higher level in CIM patients but it was not the case of the post-treatment level (p= 
0.47) (data not shown) (Table 3). 
Estradiol levels 
All patients saw their serum estradiol levels fall markedly between inclusion and the end of 
the treatment (p= 0.000014) (data not shown).  
No difference was evidenced between CIM and non-CIM patients for the estradiol level 
before chemotherapy (p= 0.49), after chemotherapy (p= 0.94) or for the variation between 
these 2 times (p= 0.36) (data not shown) (Table 3). 
 
Risk factors for CIM patients (univariate analysis) 
The comparison of other characteristics between CIM and non-CIM groups showed that CIM 
patients were 9 years older (43 versus 34; p= 0.00013), had done less fertility preservation (p= 
0.03), had a tendency to have shorter menstruations cycles (p= 0.082) and earlier onset of 
amenorrhea during chemotherapy (no. of chemotherapy cycles before amenorrhea 3 versus 4; 
p= 0.088) (Table1).  
 
Multivariate analysis 
On multivariate analysis only age was associated with menstrual status (p= 0.000022), older 
patients have greater risk to experience premature menopause. 
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DISCUSSION 
 
In this prospective multicenter study, we conducted an interim analysis on data available at 
1.5 years follow-up, i.e. 12 months post-chemotherapy, to see the feasibility and the 
preliminary results of the study.  
A total of 63 patients have been enrolled in 15 months showing a good inclusion rate and that 
the recruitment of the other 177 patients is technically feasible. Moreover the response rate ( 
80 %) of questionnaires and the hormones measurements were sufficient to perform this 
analysis and allow us to pursue this study. A particular attention should be given to 
questionnaires to limit the missing data in upcoming visits and patients. 
In order to see the preliminary results of this study, we compared patients presenting at least 
12 months of amenorrhea (CIM) to patients without amenorrhoea or with less than 12 months 
of amenorrhea (non-CIM). In this analysis, among our 58 patients, 98.3% of the patients 
experienced chemotherapy induced amenorrhea (CIA) and 70.7% had long term amenorrhea 
(or CIM) lasting at least 12 months. The incidence of CIM seems to be higher than the 
incidence found in the literature which could be explained by the chemotherapy regimen.
29,30
 
In fact, 71.1% of our patients received chemotherapy with FEC (5fluorouracile, epirubicin 
and cyclophosphamide) and Berlière et al. found approximately the same incidence of long 
term amenorrhea with FEC-based chemotherapy.
31
 
In line with previous studies, age was the main risk factor of CIM, older women have higher 
risk to become menopaused.
30,32,33
 According to Wallace and Kesley, ovarian reserve declines 
with age and only 3% remains at age 40. Therefore, among older patients, the risk of long 
term amenorrhea or early menopause is greater.
34
 This could explain the longer duration of 
amenorrhea for CIM women and these results are consistent with findings by Peterk et al. 
which showed that: “older age is strongly related to decreased menstrual bleeding” in natural 
menopause as in chemotherapy-related premature menopause.
35
  
However the global fertility preservation rate was not important (12%), it was higher in non-
CIM than CIM patients which could be explained by their younger age. Of course, younger 
women could be more interested in future pregnancy and as a consequence they could be 
more worried about pregnancy problems than older women. In contrast, our study underlines 
that younger women recover more often menstruations and are less at risk of premature 
menopause so fertility preservation should be ideally discussed with elder patients (over 40) 
desiring to have children.
36
 
In our analysis, CIM patients seemed to have shorter menstruation cycles than non-CIM 
patients. Apart from studies defining the menopause, the association between short 
menstruation cycles and menopause was not previously evidenced in breast cancer patients 
treated by chemotherapy.
11,37
 As defined by the WHO in 1996
11
, the length of menstrual cycle 
became shorter when women are closer to menopause; we can deduce that this information 
could be also predictive of menopause in our patients.  
Concerning the number of chemotherapy cycles, non-CIM patients received on average 1 
more chemotherapy cycle before the onset of amenorrhea, which means that amenorrhea 
appeared later in younger women as shown by Bines et al.
38
 This earlier onset of amenorrhea 
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could be explained by a diminished stock of ovarian follicles in older women, in this case the 
CIM patients.
35
 According to our results, older age, short menstruation cycle and faster 
amenorrhea could be predictive factors of longer CIA or premature menopause in young 
breast cancer patients treated by chemotherapy.  
The quality of life assessment focused on functional part (QLQ-C30 and QLQ-BR23) and 
climacteric symptoms (Kupperman index). It showed significantly impaired QoL shortly after 
chemotherapy in both groups of patients. This time effect concerned the 3 questionnaires 
(QLQ-C30, QLQ-BR23, and the Kupperman index) showing that chemotherapy was 
damaging for the patients’ QoL. These results are consistent with other studies and reviews 
demonstrating the negative effect of chemotherapy or other anticancer treatments on patients’ 
QoL.
39–41
 Scores obtained at 6 months post-chemotherapy on the QLQ-C30 and QLQ-BR23 
measures however exhibit a tendency to return to baseline levels, showing that many 
consequences of chemotherapy on QoL were reversible and lasted only for a short period of 
time.
41
 Before and/or after chemotherapy, all patients underwent other anticancer treatments 
such as surgery, radiotherapy and hormonotherapy which could also impact the patients QoL. 
Despite this, QoL scores were lower at the end of chemotherapy suggesting that 
chemotherapy should have more negative impact than other treatments.  
Concerning the main objective (QLQ-C30 functional score), which evaluates the functional 
part of general QoL in cancer patients; no difference was evidenced between CIM and non-
CIM patients. The score variation was quite similar showing that the functional part of general 
QoL was not affected by the CIM. This preliminary data failed to reach the same difference as 
the STIC RMI study (5 points lesser in menopaused women). In contrast, between inclusion 
and 6 months post-chemotherapy, the functional score of QLQ-BR23 decreased stronger in 
CIM patients than in non-CIM patients showing an impaired QoL. A difference of 13 points 
was also reported between them at 6 months post-chemotherapy, so the difference of 5 points 
was reached for this questionnaire. Even though these results did not reach significance, they 
underline a negative impact of menopause or CIM on patients QoL. QLQ-BR23 questionnaire 
addresses specific issues of breast cancer such as body image and sexuality whereas QLQ-
C30 is more general. The QLQ-BR23 seemed to be more precise and more adequate to 
evaluate the patients’ QoL in particular in our study. At this point of the study, we cannot 
conclude on the real incidence of CIM or its effect on functional QoL, but the results showed 
that long-term chemotherapy-induced amenorrhea has a tendency, with time, to damage the 
functional dimension of patients’ QoL measured by the QLQ-BR23. We can expect that with 
the inclusion of the next 177 patients and a longer follow-up (30 months post-chemotherapy), 
differences will reach significance and we will be able to confirm our hypotheses. The 
Kupperman index evaluates the climacteric symptoms. At the end of chemotherapy, all 
patients experienced increase of these symptoms but only CIM patients continuously reported 
the symptoms at 6 months post-chemotherapy. CIM negatively impacted the patients’ mood, 
hot flushes and vaginal dryness. The Kupperman index confirmed that CIM patients were 
closer to postmenopausal status than non-CIM patients and the differentiation based on 
amenorrhea duration seems to be a good marker.  
Concerning hormonal variations, our data showed that the overall serum AMH and estradiol 
levels decreased after chemotherapy, whereas serum FSH levels increased, confirming the 
cytotoxic effect of chemotherapy on ovarian function.
8,11,41
 As in other studies, a marked 
difference for AMH and FSH levels between inclusion and the end of chemotherapy was 
shown, but in our study this difference was also significant for estradiol.
41–43
 The comparison 
of these previous studies with our data showed that the numbers of patients included was 
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smaller than in our study: the greater power here could explain why the difference reached 
significance for estradiol variations. 
The initial AMH serum level was different between the 2 groups of patients with a higher 
level in non-CIM patients: this shows that low pre-treatment AMH level is linked to long-
term amenorrhea.
43
 In contrast, the level after chemotherapy was mainly under the detection 
threshold for both groups of patients without any difference between them. As shown by other 
previous studies, the AMH level at the end of chemotherapy is at its lowest and many patients 
has an undetectable level, which is consistent with our data.
42–44
 Concerning AMH serum 
variation between inclusion and the end of chemotherapy, a significant difference was shown 
between the 2 groups with a greater decrease among younger patients, which can be attributed 
to the difference found at baseline. On the other hand, a strong correlation between age and 
initial AMH level was evidenced, which correlates with the high level of AMH in non-CIM 
patients (younger patients). As shown by Anders et al. and Henry et al., this data suggests that 
the initial AMH serum level, in association with age, may play a role in the prediction of 
ovarian function.
43,45
 Although the prediction of CIM could help to determine the appropriate 
endocrine therapy when needed, further studies with larger cohort are needed to confirm these 
results. The final analysis of our study (with a total of 240 patients) will be much more 
informative on this issue. In addition, initial FSH level tended to differ between CIM and non-
CIM patients with a high level in CIM patients. Basal FSH level could also contribute to 
predict CIM on young patients. 
 
Limitations 
This interim analysis has some limitations, especially the small power due to a small sample 
size. Concerning AMH, it would have been more interesting to continue the measurements 
during the follow-up but we could not do this because of the considerable cost. Another 
limitation we should mention is the absence of transvaginal ultrasound performed before and 
after chemotherapy which would have strengthened the data about the ovarian reserve with 
the ovarian volume calculation and the antra follicles count.    
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CONCLUSION 
This analysis suggests that the study is technically feasible with a good inclusion rate and 
sufficient data. Preliminary results did not evidence any difference between CIM and non-
CIM patients for our main objective (impact of CIM on functional score of QLQ-C30). In 
contrast, we were able to point out that CIM patients specific QoL (evaluated by the QLQ-
BR23) is more impacted than non-CIM patients and they experienced more climacteric 
symptoms as expected. According to this result, QLQ-BR23 seems to be more appropriate to 
evaluate the young breast cancer patients QoL changes. Our results also underline that 
amenorrhea ≥ 12 months is linked to certain parameters: older age, low baseline AMH, high 
baseline FSH, shorter menstruation cycles and earlier onset of amenorrhea. In particular, 
initial AMH level seems to be more informative regarding the risk of CIM when compared to 
FSH and/or estradiol. But, these data are still insufficient to determine pre-treatment AMH 
level as a predictive factor of CIM and additional prospective studies are needed on this issue.  
We also expect the final analysis with more patients (240 planned) and a longer follow-up (30 
months post-chemotherapy) to be more precise on issues we have discussed about. 
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CLINICAL PRACTICE POINTS 
 Menopausal status is difficult to predict in young breast cancer patients treated by 
chemotherapy. Moreover, chemotherapy is known to impair the patients’ quality of 
life but the specific case of young women experiencing chemotherapy-induced 
menopause lacks of knowledge.  
 
 Our preliminary results suggest, as expected, that age is predictive of menopause. 
Other parameters like pre-treatment AMH level, in association with pre-treatment FSH 
level, shorter menstruation cycle and earlier amenorrhea seem also to be predictive of 
menopause in young women treated by chemotherapy. Additional prospective studies 
are needed to confirm these results. The EORTC QLQ-BR23 seems to be more precise 
to evaluate the quality of life than the EORTC QLQ-C30 and it tends to show an 
impaired quality of life in menopaused patients (at 6 months post-chemotherapy) 
which have to be confirmed in a larger cohort.  
 
 Clearly identifying menopausal status of young breast cancer patients could be helpful 
to determine the appropriate treatment, especially hormone therapy. Concerning the 
quality of life, supportive care could be given to young patients experiencing CIM in 
order to improve their quality of life. 
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TABLES CAPTIONS 
Table 1: Patient characteristics 
1One patient was 46 years old. She was included with the agreement of the study coordinator. 
“*” indicates a significant difference (p ≤ 0.05) between CIM and non-CIM patients. 
 CIM and non-CIM CIM Non-CIM P value 
Characteristics N  % N N  
No. patients 58 100 41 17 - 
Median age at enrolment 
(years) [range] 
40.8 [24.7 - 46]1 - 42.5 [33.3 – 46]  33.8 [24.7 – 44.1] *0.00013 
Median Body Mass Index 
(kg/m²) [range] 
22 [18 - 44] - 22 [18 – 44] 22 |18 – 34] 0.21 
Underweight (<18.5) 4 7 2 2 1.00 
Normal (18.5 – 24.9) 35 60 23 12 0.67 
Overweight (25 – 29.9)  9 16 8 1 0.70 
Obese (≥ 30) 10 17 8 2 1.00 
Performance status - - - - 0.79 
0 51 88 37 14 - 
1 4 7 2 2 - 
2 1 2 1 0 - 
Unknown 2 3 1 1 - 
Children before 
chemotherapy 
- - - - 0.48 
No 7 12 4 3 - 
≥ 1 51 88 37 14 - 
Fertility preservation 7 12 2 5 *0.03 
Smoking status - - - - 0.19 
Current 14 24 11 3 - 
Former 16 28 13 3 - 
Never 26 45 16 10 - 
Breast cancer family 
history 
30 52 20 10 0.48 
Histological type - - - - 0.30 
22 
 
Invasive ductal carcinoma 45 77.6 31 14 - 
Invasive lobular carcinoma 5 8.6 5 0 - 
Others 8 13.8 5 3 - 
Histologic grade - - - - 0.65 
I 1 2 1 0 - 
II/III 57 98 40 17 - 
Nodal status - - - - 0.27 
Positive 27 47 21 6 - 
Negative 31 53 20 11 - 
Hormonal receptors - - - - - 
Estrogen-positive 43 74 30 13 0.77 
Progesterone-positive 32 55 23 9 0.99 
HER-positive 12 21 8 4 0.7 
Neo-adjuvant 
chemotherapy 
30 52 21 9 0.9 
Chemotherapy regimens - - - - 0.29 
3FEC + 3 Taxotere 31 52.5 22 9 - 
4FEC + 4 Taxotere 11 18.6 9 2 - 
6TAC 8 13.6 5 3 - 
4AC + 4 T 6 10.2 5 1 - 
4TAC 1 1.7 0 1 - 
TCH 1 1.7 0 1 - 
Abbreviations: 
AC: doxorubicin and cyclophosphamide; FEC: 5fluorouracile, epirubicin and cyclophosphamide; SBR:   
T: docetaxel (or paclitaxel); TAC: docetaxel, adriamycin and cyclophosphamide; TCH = docetaxel (or 
paclitaxel), carboplatin and Herceptin 
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Table 2: Number of questionnaires per group and per visit 
No. of 
questionnaires 
Inclusion (V0) End of chemotherapy 
(V1) 
6 months post-
chemotherapy (V2) 
 CIM Non-CIM CIM Non-CIM CIM Non-CIM 
QLQ-C30 functional 
score 
38 17 34 14 30 14 
QLQ-BR23 
functional score 
38 17 34 14 30 14 
Kupperman index 26 15 26 14 23 11 
Abbreviations: 
QLQ-C30: Quality of Life Questionnaire-Core 30, QLQ-BR23: Quality of Life Questionnaire-Breast 23 
 
Table 3: Hormones level per group and per visit 
“*” indicates a significant difference (p ≤ 0.05) between CIM and non-CIM patients. 
Hormones Inclusion (V0) End of chemotherapy (V1) 
 CIM [range] 
(N) 
Non-CIM [range] 
(N) 
p CIM [range] 
(N) 
Non-CIM [range] 
(N) 
p 
AMH 
(pmol/L) 
3,93 [0,1 ; 
58,1] (N=40) 
13,5 [1,64 ; 69] 
(N=17) 
*0.0032 
0,1 [0 ; 0] 
(N=39) 
0,1 [0,1 ; 1,21] 
(N=15) 
0.26 
FSH (UI/L) 5,7 [1,2 ; 65] 
(N=39) 
4,5 [1,5 ; 9,5] 
(N=15) 
0.07 
91,1 [16,7 ; 
198] (N=28) 
83 [11 ; 117] 
(N=12) 
0.47 
Estradiol 
(pmol/L) 
327 [18,4 ; 
1527] (N=39) 
288 [131 ; 782] 
(N=15) 
0.49 
40 [0 ; 495] 
(N=28) 
24,5 [5 ; 1073] 
(N=12) 
0.94 
Abbreviations: 
AMH: Anti-Müllerian Hormon; FSH: Follicle Stimulating Hormone 
 
24 
 
FIGURE CAPTIONS  
 
 
Fig.1. Study design 
A total of 240 patients are expected to participate in this study and the interim analysis was 
conducted on 58 patients. To assess quality of life, patients were asked to complete the 
questionnaires several times: at inclusion before chemotherapy (V0), at the end of chemotherapy 
(V1), 6 months post-chemotherapy (V2), 18 months post-chemotherapy (V3) and 30 months post-
chemotherapy (V4). Hormonal measurements (AMH, FSH and estradiol) were done before 
chemotherapy (V0) and at the end of chemotherapy (V1). 
Abbreviations:  
AMH: Anti-Müllerian Hormone, BIQ: Body Image Questionnaire, DN4: Neuropatic pain in 4 questions, 
FSH: Follicle Stimulating Hormone, HAD: Hospital Anxiety Depression scale, LEEDS: sleeping quality 
questionnaire, QLQ-BR23: Quality of Life Questionnaire-Breast 23, QLQ-C30: Quality of Life 
Questionnaire-Core 30, VAS: Visual Analogue Scale  
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Fig.2. Flowchart of participants   
Abbreviation: 
CIM: Chemotherapy-Induced Menopause 
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a. QLQ-C30 functional score variation from inclusion to 6 months post-chemotherapy: mean 
(± 95% confidence intervals). 
 
 
b. QLQ-BR23 functional score variation from inclusion to 6 months post-chemotherapy: mean 
(± 95% confidence intervals).  
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c. Kupperman index variation from inclusion to 6 months post-chemotherapy: mean (± 95% 
confidence intervals).  
 
 
 
 
 
 
 
 
 
 
d. Analysis per dimension of Kupperman index at 6 months post-chemotherapy 
Fig.3. Quality of life measurements: QLQ-C30 functional score variations between inclusion to 6 
months post-chemotherapy (a.), QLQ-BR23 functional score variations between inclusion to 6 
months post-chemotherapy (b.), Kupperman index variations between inclusion to 6 months post-
chemotherapy (c.) and analysis per dimension of Kupperman index at 6 months pots-chemotherapy 
(d.). “*” indicates a significant difference (p ≤ 0.05) between CIM and non-CIM patients. 
* 
* 
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a. AMH serum level variation between inclusion and the end of chemotherapy: mean (± 95% 
confidence intervals) 
 
 
b. Correlation between patient’s age and their pre-treatment AMH level 
 
Fig.4. Hormone measurements: AMH serum level variations between inclusion and the end of 
chemotherapy (a.)  and Correlation between patient’s age and their pre-treatment AMH level (b.). 
“*” indicates a significant difference (p ≤ 0.05) between CIM and non-CIM patients. 
 
 
* 
* 
